Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.4K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

606
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
606
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

1.9K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peptidyl arginine deiminase 2 (PAD2) inhibition is associated with acute and long-term benefits in a murine model of traumatic brain injury.

The journal of trauma and acute care surgery·2026
Same author

Development of Next-Generation Fluoroacetamidine-Containing Activity-Based Probes for the Selective Labeling of the Protein Arginine Deiminases (PADs).

ACS chemical biology·2026
Same author

Cellular nucleic acid-binding protein (CNBP) dependent cytokine programming shapes host defense against <i>Plasmodium</i> infection.

bioRxiv : the preprint server for biology·2026
Same author

Virulence determinants and toxin profile of methicillin resistant Staphylococcus aureus from commercial cheese in Bangladesh: A public health risk.

PloS one·2026
Same author

Licensed to pore: Gasdermins in action.

Cell chemical biology·2026
Same author

Editorial Expression of Concern: DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation.

Nature immunology·2026
Same journal

Chemotactic self-organization captures the dynamics of mammalian hair follicle patterning.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Tomographic imaging of superconducting order using particle-hole interference.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Inhibitory potential of autologous neutralizing antibodies sets quantitative limits on the rebound-competent HIV-1 reservoir.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Inferring epidemiological parameters under an infectious phylogeography model with visitor dynamics.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Analytical modeling for suction cup designs for skin-interfaced wearable devices.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Improving cell-free metabolism through direct integration of artificial respiratory chains.

Proceedings of the National Academy of Sciences of the United States of America·2026
See all related articles

Related Experiment Video

Updated: Jul 19, 2025

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
06:53

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA

Published on: December 26, 2015

12.7K

Targeting STING oligomerization with small-molecule inhibitors.

Fiachra Humphries1, Liraz Shmuel-Galia1, Zhaozhao Jiang1

  • 1Division of Innate Immunity, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605.

Proceedings of the National Academy of Sciences of the United States of America
|August 7, 2023
PubMed
Summary
This summary is machine-generated.

Researchers discovered BB-Cl-amidine, a small-molecule inhibitor that blocks Stimulator of Interferon Genes (STING) signaling. This compound effectively reduces inflammatory responses driven by cytosolic DNA, offering a potential treatment for STING-related inflammatory diseases.

Keywords:
Trex-1cytokinesprotein arginine deiminasessmall-molecule inhibitorstimulator of interferon genes

More Related Videos

Genetic and Biochemical Approaches for In Vivo and In Vitro Assessment of Protein Oligomerization: The Ryanodine Receptor Case Study
12:43

Genetic and Biochemical Approaches for In Vivo and In Vitro Assessment of Protein Oligomerization: The Ryanodine Receptor Case Study

Published on: July 27, 2016

11.7K
Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
10:20

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

8.6K

Related Experiment Videos

Last Updated: Jul 19, 2025

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
06:53

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA

Published on: December 26, 2015

12.7K
Genetic and Biochemical Approaches for In Vivo and In Vitro Assessment of Protein Oligomerization: The Ryanodine Receptor Case Study
12:43

Genetic and Biochemical Approaches for In Vivo and In Vitro Assessment of Protein Oligomerization: The Ryanodine Receptor Case Study

Published on: July 27, 2016

11.7K
Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
10:20

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

8.6K

Area of Science:

  • Immunology
  • Molecular Biology
  • Drug Discovery

Background:

  • Stimulator of Interferon Genes (STING) is crucial for inflammatory responses to cytosolic DNA.
  • Aberrant STING activation is implicated in various chronic inflammatory diseases.
  • STING signaling involves cGAS, cGAMP, and downstream transcription factors like IRF3 and NFκB.

Purpose of the Study:

  • To identify and characterize a novel small-molecule inhibitor of STING.
  • To evaluate the therapeutic potential of this inhibitor in preclinical models of STING-driven inflammation.

Main Methods:

  • Screening for small-molecule inhibitors of STING.
  • Biochemical assays to assess inhibition of STING signaling pathway components (IFNs, ISGs, NFκB cytokines).
  • In vivo studies using Trex-1 mutant mice to evaluate efficacy and mechanism of action.

Main Results:

  • BB-Cl-amidine was identified as a potent STING inhibitor.
  • The compound suppressed type I IFNs, IFN-stimulated genes (ISGs), and NFκB-dependent cytokines without affecting other pattern recognition receptors.
  • BB-Cl-amidine alleviated pathology in a mouse model of cytosolic DNA accumulation.
  • Mechanistically, BB-Cl-amidine inhibited STING oligomerization via modification of Cys148.

Conclusions:

  • BB-Cl-amidine is a novel small-molecule inhibitor of STING.
  • This compound effectively blocks STING-mediated inflammatory pathways.
  • BB-Cl-amidine demonstrates therapeutic potential for treating STING-driven inflammatory diseases.